BioAge valued at $758 mln in debut as investors bet on weight …
WEB1 day ago · The debut valued BioAge at $757.5 million, compared to the $394.3 million it fetched after its February funding round, according to PitchBook data. BioAge sold 11 million shares, 46.7% more than ...
BioAge stock rallies 29% following upsized $198M IPO
WEB1 day ago · Shares of BioAge (BIOA) recently sold for $23.30, up 29% from its offering price, at around 12:20 p.m. ET. BioAge (BIOA) priced 11M shares at $18 per share. Underwriters were granted a 30-day ...
Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More …
WEB1 day ago · BioAge’s NLRP3 inhibitor, code-named BGE-100, is on track for an investigational new drug application in the second half of 2025. Fortney is BioAge’s largest shareholder with a 6.7% post-IPO ...
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
WEB20 hours ago · BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.
BioAge Labs IPO: stock price today in high-profile Nasdaq debut
WEB1 day ago · BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq. The California-based biotech priced its shares at $18. Its lead product, a weight ...
BioAge posts double-digit percentage jump after IPO; natural-gas ...
WEB1 day ago · BioAge (BIOA) shares opened at $22.50 and recently changed hands at $21.96, above their $18 IPO price. ... August PCE Report Forecasts Show More Good News on Inflation. Frank Lee Sep 25, 2024.
BioAge Labs stock soars in weight loss drug maker's IPO - Quartz
WEB1 day ago · BioAge initially said that it planned to only offer 7.5 million shares between $17 to $19 each. The company’s stock initially surged 24% to over $22 Thursday. It is trading on the Nasdaq Global ...
BioAge prices $198M IPO, validating pivot to obesity drug research
WEB2 days ago · BioAge, which is evaluating a medicine that’s meant to boost the effects of popular obesity drugs known as GLP-1 agonists, sold 11 million shares at $18 apiece in the offering. Those numbers exceed projections set by the company last week, and were accrued shortly after the company had already hiked the size of its offering by 40%.
BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEB2 days ago · BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials, including a ...
BioAge Labs, A New Obesity Treatment Name, Rockets On …
WEB1 day ago · The Richmond, Calif.-based company plans to raise $189 million by offering 10.5 million shares at a range of $17 to $19 per share, according to Renaissance Capital. But in midday trades, BioAge ...
- Some results have been removed
Skip to content